XBI Technical Analysis & ETF Price Forecast

Technical Sentiment

Overall Consensus

Sell

Buy

Technical Analysis Consensus

Sell

Buy

Moving Average Consensus

Sell

Buy

State Street SPDR S&P Biotech ETF (XBI) Moving Averages Convergence Divergence (MACD) indicator is 0.12, suggesting XBI is Strong sell.

State Street SPDR S&P Biotech ETF (XBI) 20-Day simple moving average is 126.06, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it Sell.

State Street SPDR S&P Biotech ETF (XBI) 60-Day simple moving average is 123.24, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it Sell.

Technical Analysis for XBI

Technical Sentiment Analysis for State Street SPDR S&P Biotech ETF (XBI) As of 2026-02-12, State Street SPDR S&P Biotech ETF (XBI) is exhibiting a Strong sell technical sentiment. Our proprietary analysis, which aggregates 12 technical signals, shows that 4 indicators are flashing buy, while 8 are indicating sell.

Momentum Indicators: RSI, MACD & Overbought/Oversold Status Currently, the Relative Strength Index (RSI) for XBI stands at 46.21, which suggests a Neutral condition. Meanwhile, the MACD (12, 26) indicator is at 0.12, providing a Buy signal for short-term momentum. Other oscillators like the Stochastic Oscillator at 37.09 and the Commodity Channel Index (CCI) at -100.54 further confirm a -3.56 outlook for the stock.

Support, Resistance & Moving Averages From a structural perspective, XBI is trading above its 60-day moving average of $123.24 and above its 200-day long-term moving average of $101.15. Key price levels to watch include the immediate resistance at $129.74 and strong support at $120.32. A break above $129.74 could signal a bull continuation, while falling below $120.32 may test the next Fibonacci floor at $115.59.

State Street SPDR S&P Biotech ETF (XBI) Support & Resistance Level

Name	S3	S2	S1	Pivot Points	R1	R2	R3
Classic	110.9	115.59	120.32	125.01	129.74	134.43	139.16
Fibonacci	115.59	119.19	121.41	125.01	128.61	130.83	134.43

State Street SPDR S&P Biotech ETF (XBI) Technical Indicators

2026-02-12

Name	Value
RSI_14	46.21
STOCHk_14_3_3	37.09
STOCHd_14_3_3	42.04
CCI_20	-100.54
AO_5_34	-0.34
MOM_10	-3.56
MACD_12_26_9	0.12

State Street SPDR S&P Biotech ETF (XBI) Relative Strength Index (RSI) is 46.21, creating a Neutral signal.

State Street SPDR S&P Biotech ETF (XBI) Stochastic Oscillator is 37.09, creating a Neutral signal.

State Street SPDR S&P Biotech ETF (XBI) Stochastic RSI is 42.04, creating a Neutral signal.

State Street SPDR S&P Biotech ETF (XBI) Commodity Channel Index (CCI) is -100.54, creating a Buy signal.

State Street SPDR S&P Biotech ETF (XBI) Awesome Oscillator is -0.34, creating a Sell signal.

State Street SPDR S&P Biotech ETF (XBI) Momentum is -3.56, creating a Sell signal.

State Street SPDR S&P Biotech ETF (XBI) MACD is 0.12, creating a Buy signal.

State Street SPDR S&P Biotech ETF (XBI) Moving Average

2026-02-12

Period	Simple	Signal
MA_5	124.96	Sell
MA_10	125.06	Sell
MA_20	126.06	Sell
MA_60	123.24	Sell
MA_200	101.15	Buy
MA_250	97.6	Buy

State Street SPDR S&P Biotech ETF (XBI) 5-Day simple moving average is 124.96, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Sell.

State Street SPDR S&P Biotech ETF (XBI) 10-Day simple moving average is 125.06, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Sell.

State Street SPDR S&P Biotech ETF (XBI) 20-Day simple moving average is 126.06, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Sell.

State Street SPDR S&P Biotech ETF (XBI) 60-Day simple moving average is 123.24, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Sell.

State Street SPDR S&P Biotech ETF (XBI) 200-Day simple moving average is 101.15, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Buy.

State Street SPDR S&P Biotech ETF (XBI) 250-Day simple moving average is 97.6, while State Street SPDR S&P Biotech ETF (XBI) share price is $123.18, making it a Buy.